Aberrant activation of oncogenic pathways and/or inactivation of tumor suppressive pathways, including p53, Myc, Ras and HIF, play critical roles in driving metabolic reprogramming in cancer [16, 17, 31]. This evidence concerns the gene MYC and cancer.